Ayoxxa: Bridging the gap
Cologne-based biotech Ayoxxa Biosystems GmbH announces that Rodney Turner has assumed duties as the interim CEO. Prior CEO Andreas Schmidt has stepped down.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Cologne-based biotech Ayoxxa Biosystems GmbH announces that Rodney Turner has assumed duties as the interim CEO. Prior CEO Andreas Schmidt has stepped down.
Dutch immuno-oncology company Merus has appointed John Crowley its Chief Financial Officer. Former CFO Shelley Margetson has been elevated to Chief Operating Officer.
French cellular immunotherapy company TxCell has hired ex-Novartis Lab Head Li Zhou to lead its CAR-Treg programmes. Zhou was appointed Vice President Cell Engineering in October.
Norwegion immuno-oncology play Targovax has promoted Øystein Soug, previously the company’s Chief Financial Officer, to the role of Chief Executive Officer. He succeeds Gunnar Gårdemyr, who has stepped down.

